Latest Content

The U.S. commercial launch of LYMPHIR offers a new treatment option for patients with relapsed/refractory stage 1 to 3 cutaneous T-cell lymphoma.

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options.

I share how my sister’s final days felt different from her many rebounds and how I continue to process the grief of losing her after years of anticipation.

Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera.

In November 2025, the FDA issued multiple oncology approvals that expanded treatment access for patients with breast, lung, blood and solid tumor cancers.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

I found purpose again after my myeloma diagnosis when I returned to teaching and shared my work, moments that reminded me I could still grow and reconnect.

Cindy and Katie share how finding a friend who understood the caregiving journey made the experience less isolating and helped them navigate loss and hope.

Although most patients with localized kidney cancer have high cancer-specific survival, surveys show a gap between doctor and patient perceptions of cure.

CURE recently sat down with an expert to discuss crucial information for patients with gastrointestinal stromal tumors, or GISTs.

A stamp on my Christmas cards stirred deep memories and reminded me that small actions can make a meaningful impact in the fight against breast cancer.